Episode Details

Back to Episodes
Ep. 133: Nina Deka: Healthcare Technology Still In Early Stages Of Disruption

Ep. 133: Nina Deka: Healthcare Technology Still In Early Stages Of Disruption

Episode 133 Published 4 years, 10 months ago
Description

Nina Deka, Senior Research Analyst at ROBO Global, points out some huge problems in the healthcare industry that are ripe for innovative solutions. After looking at some of five major themes, Nina revisits some stocks from her last appearance like 1Life Healthcare (ONEM) and Teladoc (TDOC) as well as the stories behind Tabula Rasa (TRHC) Akoya BioSciences (AKYA), Catalent (CTLT), Dexcom (DXCM) and Fate Therapeutics (FATE). For the video version, show notes and charts, visit investors.com/podcast.


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us